IN THIS ARTICLE
Myeloma Medications and Other Drug Therapy
Numerous chemotherapy and biological drug combinations have been used for multiple myeloma. Which type and combination of therapy depends on many factors, including the type and stage of myeloma, the ability to tolerate chemotherapy side effects, and if any previous treatment was rendered or if further treatment is planned, such as stem cell transplantation. Hematologists/oncologists often work together regionally to decide which combination of chemotherapy and biological drugs are currently working best for their patients. Because of this regional collaboration, the drug combinations often vary and are able to change rapidly when improved results occur.
Chemotherapy is given in cycles.
Chemotherapy may be given in pill form or in liquid form to be infused directly into the bloodstream through a vein (intravenous).
Bisphosphonates: All patients receiving primary therapy for multiple myeloma should receive bisphosphonates. Those in most common use are pamidronate (Aredia) an zoledronic acid (Zometa). These are not chemotherapy agents, but can reduce the frequency of symptomatic skeletal events such as fractures. They can also treat hypercalcemia.
Corticosteroids are powerful drugs that have many different actions, including anti-inflammatory and anti-immunity activity. They are active against myeloma and reduce production of the M protein. Prednisone and dexamethasone can be given with chemotherapy agents or alone for people who cannot tolerate chemotherapy drugs or need them to help to lower calcium levels or to reduce swelling around nerves being pressed upon by masses of plasma cells in or next to bones.
Immune system modifying drugs such as thalidomide or lenalidomide are not chemotherapy agents in the traditional sense. These immunomodulatory agents are usually given with a corticosteroid, such as dexamethasone (Decadron). Thalidomide's actions may include decreasing the ability of cancer spread throughout the blood (antiangiogenesis), interfering with adhesion molecules, or enhancing release of cytokines (cancer-fighting substances within the body). This drug may be associated with sleepiness, constipation, venous blood clots, and numbness and tingling in the tips of the extremities. It is absolutely contraindicated in pregnancy, as it causes birth defects. The drug is dispensed through a program that ensures that physicians have educated patients about the importance of contraception when taking the drug. Usually, aspirin or low-dose blood thinners, such as warfarin (Coumadin) are given in conjunction with thalidomide and corticosteroids.
New drug therapy
An analogue of thalidomide, CC-5013, or lenalidomide (Revlimid), purportedly has fewer side effects of thalidomide and appears to be more potent than thalidomide in laboratory studies. It is also an immunomodulatory agent. It has been evaluated as part of combined therapy with corticosteroids or chemotherapy drugs. The combination of lenalidomide ans a corticosteroid is now FDA-approved as a first-line treatment option in multiple myeloma. Currently, other immunomodulatory drugs for myeloma are also undergoing development.
Bortezomib (Velcade) is the first of a new class of medicines called proteasome inhibitors. Proteasome inhibitors may preferentially disrupt a cancer cell's growth. Other proteasome inhibitors have recently been developed and are now undergoing early clinical evaluation.
Medically Reviewed by a Doctor on 4/2/2015
Wendy Hu, MD
Clarence Sarkodee-Adoo, MD
Mary L Windle, PharmD
Jay B. Zatzkin, MD
Must Read Articles Related to Myeloma
Patient Comments & Reviews
The eMedicineHealth doctors ask about Myeloma:
Myeloma - Treatment
What was the treatment for your myeloma?
Myeloma - Prevention and Outlook
What prevention measures do you use to avoid getting myeloma?
Myeloma - Experience
Please describe your experience with myeloma.
Multiple Myeloma - Symptoms
The symptoms of multiple myeloma can vary greatly from patient to patient. What were your symptoms at the onset of your disease?